Voriconazole

C. diff Risk

Low

Oral Bioavailability

Excellent

Approximate Cost

IV-$300 PO-$100

Dosing

See drug monitoring information
IV - 6mg/kg IV q12h x 2 doses then 4mg/kg IV q12h
PO - 400mg PO q12h x 2 doses then 200mg PO q12h
Dose reduction may be required if low body weight

Severe impairment (Child-Pugh C)- Should only be used if benefit outweighs risk
Mild to moderate (Child-Pugh A/B) - Standard loading dose then reduce maintenance by 50%

General Information

Common Usage

Candida infections both mucocutaneous and invasive - i.e. Candidemia

Antifungal prophylaxis in immunocompromised

Drug Monitoring

Therapeutic drug monitoring may be helpful to ensure adequate concentrations and exclude toxicity (discuss with ID)

QTc interval in patients at elevated risk

Monitor hepatic profile

Adverse Effects

  • Drug interactions

  • QTc prolongation

  • Hepatic enzyme abnormalities

  • Rash - up to 20%

  • Visual disturbance

  • Fluorosis

  •  GI upset

Major Interactions

CYP450 interactions ++

Other QTc prolonging agents

Recommend review of pt medications due to high frequency of significant interactions

Pharmacology

Antimicrobial class: Triazole antifungal, second generation

Pregnancy category: D

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Poor